Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics

Gastroenterology

Volumn 131, Issue 6, 2006, Pages 1887-1898

  Marcello, Tobias ^a   Grakoui, Arash ^b   Barba Spaeth, Giovanna ^a   Machlin, Erica S ^a   Kotenko, Sergei V ^c   Macdonald, Margaret R ^a   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; INTERFERON LAMBDA; INTERFERON RECEPTOR; STAT PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE CONTROL; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA REPLICATION; SIGNAL TRANSDUCTION; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 33845605155     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.09.052     Document Type: Article

References (53)

1. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 47 (1998) 1-39
2. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., Hu P.Y., Miller J.K., Gerber M.A., Sampliner R.E., et al., The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 327 (1992) 1899-1905
3. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
4. Fishman J.A., Rubin R.H., Koziel M.J., and Periera B.J. Hepatitis C virus and organ transplantation. Transplantation 62 (1996) 147-154
5. Reichard O., Schvarcz R., and Weiland O. Therapy of hepatitis C: α interferon and ribavirin. Hepatology 26 (1997) 108S-111S
6. Foser S., Weyer K., Huber W., and Certa U. Improved biological and transcriptional activity of monopegylated interferon-α-2a isomers. Pharmacogenomics J 3 (2003) 312-319
7. McHutchison J.G. Hepatitis C advances in antiviral therapy: what is accepted treatment now?. J Gastroenterol Hepatol 17 (2002) 431-441
8. Lindenbach B.D., and Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 436 (2005) 933-938
9. Cheney I.W., Lai V.C., Zhong W., Brodhag T., Dempsey S., Lim C., Hong Z., Lau J.Y., and Tam R.C. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by α, β, and γ interferons. J Virol 76 (2002) 11148-11154
10. Frese M., Barth K., Kaul A., Lohmann V., Schwarzle V., and Bartenschlager R. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-α. J Gen Virol 84 (2003) 1253-1259
11. Frese M., Pietschmann T., Moradpour D., Haller O., and Bartenschlager R. Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 82 (2001) 723-733
12. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., and Bartenschlager R. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35 (2002) 694-703
13. Guo J.T., Bichko V.V., and Seeger C. Effect of α interferon on the hepatitis C virus replicon. J Virol 75 (2001) 8516-8523
14. Lanford R.E., Guerra B., Lee H., Averett D.R., Pfeiffer B., Chavez D., Notvall L., and Bigger C. Antiviral effect and virus-host interactions in response to α interferon, γ interferon, poly(i)-poly(c), tumor necrosis factor α, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 77 (2003) 1092-1104
15. Wang C., Pflugheber J., Sumpter Jr. R., Sodora D.L., Hui D., Sen G.C., and Gale Jr. M. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77 (2003) 3898-3912
16. Zhu H., and Liu C. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol 77 (2003) 5493-5498
17. Lindenbach B.D., Evans M.J., Syder A.J., Wölk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., and Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
18. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 14 (2001) 778-809
19. Katze M.G., He Y., and Gale Jr. M. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2 (2002) 675-687
20. Brierley M.M., and Fish E.N. Review: IFN-α/β receptor interactions to biologic outcomes: understanding the circuitry. J Interferon Cytokine Res 22 (2002) 835-845
21. Goodbourn S., Didcock L., and Randall R.E. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81 (2000) 2341-2364
22. Larkin J., Jin L., Farmen M., Venable D., Huang Y., Tan S.L., and Glass J.I. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res 23 (2003) 247-257
23. Seo S.H., and Webster R.G. Tumor necrosis factor α exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol 76 (2002) 1071-1076
24. Kawanishi Y., Hayashi N., Katayama K., Ueda K., Takehara T., Miyoshi E., Mita E., Kasahara A., Fusamoto H., and Kamada T. Tumor necrosis factor-α and interferon-γ inhibit synergistically viral replication in hepatitis B virus-replicating cells. J Med Virol 47 (1995) 272-277
25. Benedict C.A. Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev 14 (2003) 349-357
26. Langer J.A., Cutrone E.C., and Kotenko S. The class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 15 (2004) 33-48
27. Kotenko S.V., and Langer J.A. Full house: 12 receptors for 27 cytokines. Int Immunopharmacol 4 (2004) 593-608
28. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., McKnight G., Clegg C., Foster D., and Klucher K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4 (2003) 63-68
29. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., and Donnelly R.P. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4 (2003) 69-77
30. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., and Paludan S.R. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80 (2006) 4501-4509
31. Donnelly R.P., Sheikh F., Kotenko S.V., and Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 76 (2004) 314-321
32. Robek M.D., Boyd B.S., and Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79 (2005) 3851-3854
33. Lau J.F., and Horvath C.M. Mechanisms of type I interferon cell signaling and STAT-mediated transcriptional responses. Mt. Sinai J Med 69 (2002) 156-168
34. Ramana C.V., Gil M.P., Schreiber R.D., and Stark G.R. Stat1-dependent and -independent pathways in IFN-γ-dependent signaling. Trends Immunol 23 (2002) 96-101
35. de Veer M.J., Holko M., Frevel M., Walker E., Der S., Paranjape J.M., Silverman R.H., and Williams B.R. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69 (2001) 912-920
36. Der S.D., Zhou A., Williams B.R., and Silverman R.H. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci U S A 95 (1998) 15623-15628
37. Gale Jr. M. Effector genes of interferon action against hepatitis C virus. Hepatology 37 (2003) 975-978
38. Rani M.R., Foster G.R., Leung S., Leaman D., Stark G.R., and Ransohoff R.M. Characterization of β-R1, a gene that is selectively induced by interferon β (IFN-β) compared with IFN-α. J Biol Chem 271 (1996) 22878-22884
39. Blight K.J., McKeating J.A., Marcotrigiano J., and Rice C.M. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77 (2003) 3181-3190
40. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., and Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80 (2006) 1734-1741
41. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., and Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 75 (2001) 1252-1264
42. Brand S., Zitzmann K., Dambacher J., Beigel F., Olszak T., Vlotides G., Eichhorst S.T., Goke B., Diepolder H., and Auernhammer C.J. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-λs IL-28A and IL-29. Biochem Biophys Res Commun 331 (2005) 543-548
43. Radaeva S., Jaruga B., Hong F., Kim W.H., Fan S., Cai H., Strom S., Liu Y., El-Assal O., and Gao B. Interferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122 (2002) 1020-1034
44. Taylor M.W., Grosse W.M., Schaley J.E., Sanda C., Wu X., Chien S.C., Smith F., Wu T.G., Stephens M., Ferris M.W., McClintick J.N., Jerome R.E., and Edenberg H.J. Global effect of PEG-IFN-α and ribavirin on gene expression in PBMC in vitro. J Interferon Cytokine Res 24 (2004) 107-118
45. Coccia E.M., Severa M., Giacomini E., Monneron D., Remoli M.E., Julkunen I., Cella M., Lande R., and Uze G. Viral infection and toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34 (2004) 796-805
46. Dumoutier L., Lejeune D., Hor S., Fickenscher H., and Renauld J.C. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J 370 (2003) 391-396
47. Dumoutier L., Tounsi A., Michiels T., Sommereyns C., Kotenko S.V., and Renauld J.C. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-(λ)1: similarities with type I interferon signaling. J Biol Chem 279 (2004) 32269-32274
48. Lasfar A., Lewis-Antes A., Smirnov S.V., Anantha S., Abushahba W., Tian B., Reuhl K., Dickensheets H., Sheikh F., Donnelly R.P., Raveche E., and Kotenko S.V. Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma. Cancer Res 66 (2006) 4468-4477
49. Dondi E., Pattyn E., Lutfalla G., Van Ostade X., Uze G., Pellegrini S., and Tavernier J. Down-modulation of type 1 interferon responses by receptor cross-competition for a shared Jak kinase. J Biol Chem 276 (2001) 47004-47012
50. Clemens M.J. Interferons and apoptosis. J Interferon Cytokine Res 23 (2003) 277-292
51. Guo J.T., Zhu Q., and Seeger C. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol 77 (2003) 10769-10779
52. Lauer G.M., and Walker B.D. Hepatitis C virus infection. N Engl J Med 345 (2001) 41-52
53. Sheikh F., Baurin V.V., Lewis-Antes A., Shah N.K., Smirnov S.V., Anantha S., Dickensheets H., Dumoutier L., Renauld J.C., Zdanov A., Donnelly R.P., and Kotenko S.V. Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol 172 (2004) 2006-2010